These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26477611)

  • 1. Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
    Shimada M; Okawa H; Kondo Y; Maejima T; Kataoka Y; Hisamichi K; Maekawa M; Matsuura M; Jin Y; Mori M; Suzuki H; Shimosegawa T; Mano N
    Tohoku J Exp Med; 2015 Nov; 237(3):173-82. PubMed ID: 26477611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
    Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
    Noda S; Shioya M; Hira D; Fujiyama Y; Morita SY; Terada T
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):269-72. PubMed ID: 23673446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
    Shimada M; Okawa H; Maejima T; Yanagi T; Hisamichi K; Matsuura M; Akasaka K; Tsuchiya M; Kondo Y; Shimosegawa T; Mori M; Maekawa M; Suzuki H; Mano N
    Tohoku J Exp Med; 2014 Jun; 233(2):103-12. PubMed ID: 24872323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
    Fucile C; Marenco S; Bazzica M; Zuccoli ML; Lantieri F; Robbiano L; Marini V; Di Gion P; Pieri G; Stura P; Martelli A; Savarino V; Mattioli F; Picciotto A
    Med Oncol; 2015 Jan; 32(1):335. PubMed ID: 25429830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
    Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
    BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
    Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Kochi T; Suetsugu A; Shiraki M; Shimizu M
    Int J Mol Sci; 2015 Apr; 16(5):9612-24. PubMed ID: 25927582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
    Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
    Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Shoji H; Yoshio S; Mano Y; Doi H; Sugiyama M; Osawa Y; Kimura K; Arai T; Itokawa N; Atsukawa M; Aoki Y; Fukai M; Taketomi A; Mizokami M; Kanto T
    Int J Cancer; 2017 Sep; 141(5):1011-1017. PubMed ID: 28555943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
    World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
    Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
    Lesmana LA; Gani RA; Hasan I; Waspodo A; Boedi P; Luwia MS; Ganggaiswari A
    Acta Med Indones; 2012 Jul; 44(3):228-32. PubMed ID: 22983078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
    Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.